Anti-Inflammatory Therapeutics Market
Report ID: SQMIG35H2385
Report ID: SQMIG35H2385
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2385 |
Region:
Global |
Published Date: January, 2026
Pages:
173
|Tables:
117
|Figures:
70
Global Anti-Inflammatory Therapeutics Market size was valued at USD 107.32 Billion in 2024 and is poised to grow from USD 112.47 Billion in 2025 to USD 163.65 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026–2033).
Increasingly experienced autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD), resulting in a burgeoning global anti-inflammatory therapeutics market growth. With these diseases, their health systems remain always burdened globally. Within these most-prized items, biologics and targeted therapies have caused a marked improvement in treatment outcomes. Economy of scale and intuitive access to state-of-the-art therapies also come along with biosimilars.
For instance, AbbVie's biotech Humira, whose promotions are still high from the populous market in 2024 in the United States. This happened because several biosimilars came into the market, thus enhancing competition for and reducing patient costs. The aging population which suffers chronic inflammation will also propel this demand to increase. There would be many approvals for pipeline biologics focusing on the interleukin pathways, thus contributing to long-term growth in this field and shifting toward precision medicine.
How is AI Transforming Anti-Inflammatory Drug Development?
AI is causing a paradigm shift in drug development in the global anti-inflammatory therapeutics market outlook by speeding up drug development, increasing clinical trial success, and enabling more precise forms of medicine. AI platforms mine large genomic and clinical datasets for new inflammatory pathways and better drug efficacy predictions. In 2024, Sanofi and Exscientia partnered to provide new anti-inflammatory drugs using AI technologies for target discovery and compound optimization. AI is also increasingly refining clinical trial design by identifying appropriate patient cohorts to reduce failure rates. After 2025, it is expected that healthcare institutions and pharmaceutical companies will increasingly use AI to individualize treatment regimens to increase their effectiveness and reduce adverse effects in diseases like IBD and rheumatoid arthritis.
Market snapshot - 2026-2033
Global Market Size
USD 101.32 Billion
Largest Segment
Hospital Pharmacies
Fastest Growth
Retail Pharmacies
Growth Rate
4.14% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per the 2024 anti-inflammatory therapeutics market analysis, the anti-inflammatory biologics segment, the more effective ones that treat chronic inflammatory conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis-could cover the world market. In contrast with NSAIDS and corticosteroids that do not alter the immunological pathways, biologics do, allowing for long-term relief with fewer relapses. In 2024, AbbVie's Humira and its biosimilars generated significant revenues worldwide. Biologics remain the best in most areas of therapy, as indicated by the steady demand for Amgen's Enbrel.
The use of NSAIDs is expected to steadily increase, as these drugs are commonly used by patients to relieve pain and inflammation associated with arthritic conditions after collections and sports injuries. Since they are very affordable and available without prescriptions, these drugs can be accessed by a large population. For instance, retail pharmacies in the U.S. and India mentioned that NSAID sales were witnessing growth in 2024, and this trend might continue to grow.
As per the 2024 anti-inflammatory therapeutics market forecast, the market is predominantly controlled by hospital pharmacies, especially for biologics and other new therapies that require close physician intervention and infusion service facilities. These pharmacies continue to be the preferred source of specialty therapies because they can control the temperature of the product and provide safety. In 2024, hospitals in the United States reported administering more biologic infusions for autoimmune diseases. Consequently, specialty hospital pharmacists became the primary source for advanced anti-inflammatory therapies.
Whereas the retail pharmacies category is anticipated to have the highest anti-inflammatory therapeutics market share should fare well as patients will have more access to oral biologics, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). Print adoption is being accelerated by increased patient use of e-prescribing and patients wanting convenience. Chain retail pharmacies in India such as Apollo Pharmacy expanded their specialty drug departments in 2024. This helps indicate that patients willing to fill new prescriptions will pay more to purchase medications from retail outlets.
To get detailed segments analysis, Request a Free Sample Report
As per the anti-inflammatory therapeutics market regional analysis, popularity of anti-inflammatory drugs was maximal in North America assisted by a well-placed health system, insurance coverage, and high biological utilization. The region observed the largest Humira biosimilar launches, bringing treatment costs down. Big companies, including Pfizer, Amgen, and AbbVie, invest heavily in research and development for AI-enabled therapies and next-generation biologics. North America is expected to continue to maintain its fore position in IBD and rheumatoid arthritis therapies.
The illnesses commonly affecting people in the United States include inflammatory bowel disease, asthma, and arthritis. Several Humira biosimilars were authorized by the FDA in 2024, including those manufactured by Samsung Bioepis and Amgen. This made them more affordable. The widespread use of specialty pharmacies has made it easier to use biology. Large infusion centers that would further bolster the nation's position as a leader in cutting-edge anti-inflammatory medications are expected to be built by hospitals in the U.S.
Government policies favoring access to biologics and biosimilars have helped expand the anti-inflammatory therapeutics market in Canada. The Canadian Agency for Drugs and Technologies in Health (CADTH) recommended broader reimbursement for certain biosimilars in 2024. Therefore, these medicines gained more utilization in rheumatology. Collaborative research with U.S. pharmaceutical companies tends to favor the nation as well. Increased consumption of oral anti-inflammatories and the desire for affordable alternatives will drive growth.
Europe is a stronghold due to its low-cost avocation, great biosimilar usage, and benevolent healthcare legislation. The EMA approved several biosimilars in 2024 to lower the expenses incurred for the treatment of autoimmune disorders. The use of biosimilars abounds in gastroenterology and rheumatology, with France, Germany, and the UK leading the market in this field. Moving dalej with its market share via distribution of biologics to hospital portals and more advanced reimbursement plans.
The UK anti-inflammatory therapeutics sector gains from strong NHS support for biosimilars and cost-containment measures. In 2024, NHS England greatly reduced treatment costs for arthritis patients by granting them access to biologics and biosimilars. More individuals are using prescriptions as the government is working on lowering their costs and employing digital tools. By 2025, as the need for targeted therapies and oral biologics rises, the UK shall, in all probability, increase its European market share.
Reimbursement is strong in France, where biologics find a huge market. The French healthcare system, in 2024, focused more on biosimilars to reduce costs in gastroenterology and rheumatology. Increased investment of Paris-based Sanofi into AI-driven drug discovery will assist the sector in generating innovative ideas. There would be a massive increase in biosimilar use, particularly through hospitals and hospital pharmacies, which would facilitate access for patients with chronic inflammatory diseases requiring the medicines.
Germany is the leading pharmaceutical market in Europe, due to a very strong pharmaceutical industry, R&D expenditures, and patient-friendly regulations. In 2024, the German government took the lead in lowering the cost of biosimilars by facilitating their prescription. Innovation in the U.S. was driven by companies such as Boehringer Ingelheim, which worked on new biologic pipelines for autoimmune diseases. By 2025, Germany is predicted to boost the implementation of next-generation targeted therapeutics. Thus, Germany will remain the largest and most developed market for anti-inflammatory medicines in Europe.
A lot of movements in the healthcare infrastructures are best encouraged by the fact that autoimmune diseases are increasingly on the rise. Biologics adoption in China and India saw a boost in 2024 courtesy of price controls and local production policies. By 2025, Asia-Pacific is expected to act as a major engine for growth in the global anti-inflammatory therapeutics industry as they become known and favored in collaboration with big pharmaceutical companies worldwide.
India's market is rapidly expanding due to raised healthcare costs and increased incidences of asthma and arthritis cases. In 2024, the grand Indian biopharma house Biocon extended its portfolio of biosimilars for domestic and export markets alike. It has gained a following in urban and semi-urban areas among the price-sensitive public. By 2025, a strong growth of the market would be seen in India with the advent of further biosimilars and NSAIDs through retail pharmacies.
Due to strong domestic biopharma manufacturing and government-sustained healthcare reform, China is one of the fastest-growing markets. In 2024, Shanghai Henlius Biotech launched new biosimilars for autoimmune disorders, thus intensifying competition in China. Due to new price cuts instituted by the government, it has become even more convenient for patients to receive the treatment they need. It is expected that by 2025, China would lead Asia-Pacific because of better insurance coverage and the use of biologics in urban hospitals.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rise in Chronic and Autoimmune Conditions
Rising Usage of Targeted Treatments and Biologics
High Price for Medicines and Biologics
Safety Concerns and Adverse Reactions
Request Free Customization of this report to help us to meet your business objectives.
The global anti-inflammatory therapeutics market continues to evolve as many different pharmaceutical companies develop new approaches to secure a significant share of the market. Market development is mainly driven by the increasing incidence of inflammatory diseases and the increasing demand for effective treatment options by patients and healthcare professionals. Companies continue to invest time and resources into the discovery of new therapies and the refinement of existing therapies to achieve more effective and patient-friendly options.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the anti-inflammatory therapeutics industry is going through a major transition. New competitors, ideas, and more newly introduced options revolve around the industry. Companies take note of the expiration of previous blockbusters such as Humira and turn their eyes toward developing safer and more effective targeted biologics and orally available small molecules. Market interest has been piqued as a result of expanded regulatory incentives and a profound level of unmet need by pushing headlong into rare autoimmune and niche inflammatory disorders. Some examples include recent approvals such as AbbVie's extension of Rinvoq and Skyrizi and Amgen's Uplizna for IgG4-related illness. More growth is expected through differentiated pipelines and larger indications, despite a few hurdles, like Novartis' Cosentyx failing late-stage studies for giant cell arteritis.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 107.32 Billion |
| Market size value in 2033 | USD 163.65 Billion |
| Growth Rate | 4.8% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Anti-Inflammatory Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Anti-Inflammatory Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Anti-Inflammatory Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Anti-Inflammatory Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
